(Ars Technica) – The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will “urgently accelerate development” of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. (Read More)